Usefulness of a screening test for pancreatic cancer by detection of gene mutations in duodenal juice collected using secretin and a specially-made catheter following gastrointestinal endoscopy in high-risk individuals

Investigation of the usefulness of a screening test for pancreatic cancer based on highly sensitive detection of gene mutations in duodenal juice collected using synthetic human secretin and a specially-made catheter following conventional gastrointestinal endoscopy in high-risk individuals

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051200116

Enrollment

120

Registered

2021-01-22

Start date

2021-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer pancreatic cancer

Interventions

Synthetic secretin 0.2 mcg/kg is injected intravenously prior to gastrointestinal endoscopy over 1 minute and a specially-made catheter is used to collect duodenal juice following conventional gastroi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient-provided informed consent and over 20 years old 2) Patients in high-risk groups for pancreatic cancer (Onomichi City Cohort, Matsue City Cohort, Kokugan Cohort, Osaka National Cancer Center Cohort, Wakayama Medical University Cohort, Aichi Cancer Center Cohort) on whom EUS,EUS-FNA, or ERCP will be performed 3) Persons who have given their written consent to participate in this research

Exclusion criteria

Exclusion criteria: 1) Patients with hypersensitivity to secretin or other ingredients (excipients: cysteine hydrochloride and mannitol) 2) Patients in remission from acute pancreatitis or acute exacerbations of chronic pancreatitis within 2 weeks of the start of administration of the study drug 3) Patients who don't discontinue anticholinergic drugs at least 5 half-lives prior to the start of administration of the study drug 4) Pregnant or lactating women 5) Patients who received other research drugs or investigational drugs within 3 months of the start of administration of the study drug 6) Patients who are hard to observe a duodenal papilla with an endoscope 7) Patients whom the doctor in charge judges inappropriate

Design outcomes

Primary

Measure	Time frame
Sensitivity, specificity, and predictive values for detecting pancreatic cancer	—

Secondary

Measure	Time frame
Volume of the collected duodenal juice Adverse events within next day after administration of the study drug	—

Contacts

Public ContactHidenori Tanaka

Graduate School of Medicine, Osaka University

htanaka@ent.med.osaka-u.ac.jp+81-6-6879-3360

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026